Beta-O2 is a clinical stage Israeli company, leading the field of diabetes cure. Beta-O2 has developed ßAir the first ever bio-artificial pancreas for implantation in diabetic individuals. The ßAir is the ultimate treatment for T1D patients, all of whom are insulin dependent. The ßAir is a small device, implanted in a minimally invasive procedure. The device contains islets of Langerhans (insulin-and glucagon producing cells), protected from the host immune system. These cells (originating in donors, animals or human stem cells) are continuously oxygenated through Beta-O2’s proprietary technology. The distinguishing feature of ßAir is that it provides oxygen directly to the islets and provides very effective immune protection against the host immune system. In fact, the immune protection has been demonstrated so efficient that it allows implantation in animals and in human, without the need for immunosuppressive drugs.